308 related articles for article (PubMed ID: 17040892)
1. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay LJ; Griffiths ID;
Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
[TBL] [Abstract][Full Text] [Related]
2. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
3. Rheumatologists' judgements about the efficacy of anti-TNF therapy in two neighbouring regions.
Kee F; Sheehy N; O'Hare L; Bane C; Bell A; Dempster M; FitzGerald O
Rheumatology (Oxford); 2005 Nov; 44(11):1407-13. PubMed ID: 16030081
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
5. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
Fautrel B; Flipo RM; Saraux A
Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
[TBL] [Abstract][Full Text] [Related]
6. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
7. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
Vander Cruyssen B; Ribbens C; Boonen A; Mielants H; de Vlam K; Lenaerts J; Steinfeld S; Van den Bosch F; Dewulf L; Vastesaeger N
Ann Rheum Dis; 2007 Aug; 66(8):1072-7. PubMed ID: 17261531
[TBL] [Abstract][Full Text] [Related]
9. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
10. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
Marshall NJ; Wilson G; Lapworth K; Kay LJ
Rheumatology (Oxford); 2004 Aug; 43(8):1034-8. PubMed ID: 15150436
[TBL] [Abstract][Full Text] [Related]
11. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
Verstappen SM; Watson KD; Lunt M; McGrother K; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2010 Aug; 49(8):1570-7. PubMed ID: 20444856
[TBL] [Abstract][Full Text] [Related]
12. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
13. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
[TBL] [Abstract][Full Text] [Related]
15. The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy.
Watson K; Hyrich K
Musculoskeletal Care; 2003 Mar; 1(1):58-64. PubMed ID: 20217664
[No Abstract] [Full Text] [Related]
16. Regional review of patients with psoriatic arthritis in secondary care in the West Midlands: prevalence, disease activity and eligibility for anti-tumour necrosis factor therapy.
Bateman J; Cardy CM; Khan SY; Menon A; Obrenovic K; Rowe IF; Erb N
Clin Exp Rheumatol; 2009; 27(6):935-9. PubMed ID: 20149308
[TBL] [Abstract][Full Text] [Related]
17. Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria.
Geens E; Geusens P; Vanhoof J; Berghs H; Praet J; Esselens G; Lens S; Dufour JP; Vandenberghe M; Van Mullem X; Westhovens R; Verschueren P
Rheumatology (Oxford); 2009 May; 48(5):546-50. PubMed ID: 19254920
[TBL] [Abstract][Full Text] [Related]
18. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
19. British Society for Rheumatology Biologics Register.
Silman A; Symmons D; Scott DG; Griffiths I
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
[TBL] [Abstract][Full Text] [Related]
20. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?
Wadström H; Eriksson JK; Neovius M; Askling J;
Scand J Rheumatol; 2015; 44(1):22-8. PubMed ID: 25379815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
